The new EU Medical Devices and In Vitro Diagnostic Regulations are poised to reshape the European medical devices industry, introducing additional hurdles for the development and commercialization of innovative products. Small and medium sized medtech enterprises must consider their commercial strategies to ensure a seamless transition and continued access in the marketplace.
Sidley and ISS will host an afternoon of interactive discussions to help Swiss medtech companies tackle the burden of increased clinical data.
Our respected panel of speakers will share helpful tips and best practices for the challenges and opportunities that lie ahead for Swiss medtech enterprises.
- Regulatory burden of clinical/performance data
- Post marketing follow-up
- Safeguarding your supply chain
Click here to view the program.
For more information or questions, please contact firstname.lastname@example.org.
The event is open to representatives of medtech companies with a strategic role as well as PE investors but also to representatives of life sciences companies in general. Feel free to forward this invitation to your in-house colleagues. There is no registration fee to attend this event.